- In January 2025, BIOTRONIK announced the first patient enrollment in the second arm of the BIO-CONDUCT study, an FDA-approved investigational device exemption (IDE) trial examining the use of stylet-driven leads for Conduction System Pacing (CSP). This study aims to further evaluate the use of the investigational BIOTRONIK next-generation Solia CSP S pacing lead when implanted in the left bundle branch area, an emerging technique for more physiologic cardiac tissue activation in patients needing ventricular pacing
- In December 2024, Abbott announced the first-in-world leadless pacing procedures in the left bundle branch area of the heart, representing a significant advancement in leadless pacing technology. This development builds upon the company's commitment to less invasive and more physiological pacing solutions
- In November 2024, Abbott launched its AVEIR VR single-chamber ventricular leadless pacemaker system in India for the treatment of patients with slow heart rhythms. This marks a significant advancement for patient care in India, offering a leadless option with unique mapping capabilities and longer projected battery life.
- In October 2024, Medtronic received FDA approval for its Affera Mapping and Ablation System and Sphere-9 Catheter, marking a new paradigm in electrophysiology. This first-of-its-kind, all-in-one HD-mapping and dual-energy (pulsed field and radiofrequency) ablation catheter is highly anticipated for its innovation and demonstrated safety in treating atrial fibrillation
- In May 2024, Medtronic celebrated 10 years of its Reveal LINQ Insertable Cardiac Monitor (ICM) by adding artificial intelligence (AI) algorithms. This enhancement aims to reduce false alerts and improve the accuracy of cardiac event detection, further advancing long-term heart rhythm monitoring
- In March 2024, BIOTRONIK introduced the world's first and only system CE-approved for Left Bundle Branch Area Pacing (LBBAP). This complete Conduction System Pacing (CSP) solution offers a more physiological approach to pacing, potentially improving outcomes for patients needing ventricular pacing support
- In February 2024, BIOTRONIK announced that it would solely supply its proprietary DX models for new single-chamber ICD implants moving forward. This decision was based on clinical data demonstrating superior diagnostics and decreased complication risk of DX technology compared to traditional high-voltage systems
- In January 2024, Abbott announced the first global procedures in a clinical trial of its Volt Pulsed Field Ablation System, designed to treat patients with abnormal heart rhythms. This system aims to provide a new therapy option for atrial fibrillation using high-energy electrical pulses.
- In July 2023, Abbott received FDA approval for the world's first dual-chamber leadless pacemaker system, the AVEIR DR. This significant milestone expands leadless pacing options for patients requiring dual-chamber therapy, reducing the need for traditional leads and pockets
- In May 2023, Abbott received FDA approval for its Tacti Flex Ablation Catheter for the treatment of abnormal heart rhythm. This device features a flexible tip and contact force technology designed to improve procedural efficiency and patient outcomes during cardiac ablation procedures
